Indaptus Therapeutics Stock EBITDA
| INDP Stock | USD 1.03 0.03 3.00% |
Indaptus Therapeutics fundamentals help investors to digest information that contributes to Indaptus Therapeutics' financial success or failures. It also enables traders to predict the movement of Indaptus Stock. The fundamental analysis module provides a way to measure Indaptus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Indaptus Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -15.4 M | -16.2 M |
Indaptus | EBITDA |
Indaptus Therapeutics Company EBITDA Analysis
Indaptus Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Indaptus Therapeutics EBITDA | (15.42 M) |
Most of Indaptus Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Indaptus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Indaptus EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as EBITDA. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Indaptus Ebitda
According to the company disclosure, Indaptus Therapeutics reported earnings before interest,tax, depreciation and amortization of (15.42 Million). This is 101.76% lower than that of the Biotechnology sector and 115.4% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.4% higher than that of the company.
Indaptus EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in ebitda category among its peers.
Indaptus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Indaptus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Indaptus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Indaptus Therapeutics' value.| Shares | Ubs Group Ag | 2024-06-30 | 692 | Bangor Savings Bank | 2024-09-30 | 400 | Wells Fargo & Co | 2024-06-30 | 64.0 | Bank Of America Corp | 2024-06-30 | 42.0 | Jpmorgan Chase & Co | 2024-06-30 | 15.0 | Group One Trading, Lp | 2024-06-30 | 7.0 | Qube Research & Technologies | 2024-06-30 | 1.0 | Fmr Inc | 2024-09-30 | 0.0 | Massmutual Trust Co Fsb/adv | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 256.3 K | Investment House Llc | 2024-09-30 | 100 K |
Indaptus Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 2.92 M | ||||
| Shares Outstanding | 10.2 M | ||||
| Shares Owned By Insiders | 26.67 % | ||||
| Shares Owned By Institutions | 5.99 % | ||||
| Number Of Shares Shorted | 138.7 K | ||||
| Price To Book | 1.70 X | ||||
| EBITDA | (15.42 M) | ||||
| Net Income | (15.42 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 175.05 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | (13.41 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (1.70) X | ||||
| Target Price | 8.5 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 10.2 M | ||||
| Total Asset | 14.92 M | ||||
| Retained Earnings | (45.42 M) | ||||
| Working Capital | 11.22 M | ||||
| Net Asset | 14.92 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Indaptus Stock
| 0.73 | VALN | Valneva SE ADR | PairCorr |
| 0.74 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Indaptus Stock
| 0.42 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.42 | RNXT | RenovoRx | PairCorr |
| 0.35 | KZR | Kezar Life Sciences | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.